Title : Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach.

Pub. Date : 2019 Jul

PMID : 31044521






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The model reasonably predicted clinically observed acalabrutinib DDI with the CYP3A perpetrators itraconazole (4.80-fold vs. 5.21-fold observed) and rifampicin (0.21-fold vs. 0.23-fold observed). Itraconazole cytochrome P450 family 3 subfamily A member 4 Homo sapiens